Trough-to-peak ratio and circadian blood pressure profile after treatment with once-daily extended-release diltiazem, 240 mg, in patients with mild-to-moderate essential hypertension

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 3, 1997, Pages 316-322

  Coca, A ^a   Sobrino, J ^b   Soler, J ^b   Modol J ^b   Palos, M A ^b   Minguez A ^b   Esque J ^b   Plana, J ^b   Cases, M ^b   Closas, J ^b   De La Sierra, A ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

Ambulatory blood pressure monitoring; Diltiazem extended release; Hypertension; Trough to peak ratio

Indexed keywords

DILTIAZEM; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SPAIN; SUSTAINED RELEASE PREPARATION;

ADULT; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; DELAYED-ACTION PREPARATIONS; DILTIAZEM; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 17144440822     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199703000-00003     Document Type: Article

References (53)

1. Spivack C, Ocken S, Frishman WH. Calcium antagonists: its clinical use in the treatment of systemic hypertension. Drugs 1983;25:154-77.
2. Chaffman M, Brogden RN. Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs 1985;29: 387-454.
3. Halperin AK, Cubeddu LX. The role of calcium channel blockers in the treatment of hypertension. Am Heart J 1986;111:363-82.
4. Frishman WH, Rosenberg A, Katz B. Calcium antagonists in the management of systemic hypertension: the impact of sustained release drug-delivery systems. Coronary Artery Dis 1994;5:4-13.
5. World Health Organization/International Society of Hypertension. The 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993;11:905-18.
6. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-83.
7. Kaplan NM. Calcium entry blockers in the treatment of hypertension: current status and future prospects. JAMA 1989;262:817-23.
8. Anderson KE, Johannson BW, Olson SOR. Preclinical and clinical aspects on calcium entry blockers with special emphasis on diltiazem in the treatment of angina pectoris. Acta Pharmacol Toxicol 1985;57(suppl):1-45.
9. Cutler NR, Eff J, Fromell G, et al. Dose-ranging study of a new, once-daily diltiazem formulation for patients with stable angina. J Clin Pharmacol 1995;35:189-95.
10. Hammond PG, Pleskow W, Pleskow S, et al. Once-a-day antihypertensive therapy: comparison of extended-release diltiazem HCl and extended-release nifedipine. Cardiovasc Res Rep 1994;15: 46-58.
11. Graney WF. Clinical experience with a once-daily extended-release formulation of diltiazem in the treatment of hypertension. Am J Med 1992;93(suppl 2A):56s-64s.
12. Frishman WH. A new extended-release formulation of diltiazem HCl for the treatment of mild-to-moderate hypertension. J Clin Pharmacol 1993;33:612-22.
13. Fiddes R, Heym H, Hilty W, et al. Blood pressure control with diltiazem XR, a novel extended-release formulation of diltiazem HCl, in mature and elderly hypertensive patients. Clin Ther 1994;16:209-21.
14. Whelton A, Eff J, Magner DJ. Sustained antihypertensive activity of diltiazem SR: double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring. J Clin Pharmacol 1992;32:808-15.
15. Black HR. Prescribing for compliance: the role of fixed-dose combinations. Consultant 1988;28:145-52.
16. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4.
17. Fujii J, Seki A. Compliance and compliance-improving strategies in hypertension: the Japanese experience. J Hypertens 1985; 3(suppl 1):19-22.
18. Meredith PA. Trough/peak ratios for antihypertensive agents: the issues in perspective. Drugs 1994;48:661-6.
19. Lipicky RJ. Trough:peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens 1994;12(suppl 8):s17-9.
20. Bialer M, Hadad S, Golomb G, et al. Pharmacokinetic analysis of the two new sustained-release products of diltiazem designed for twice- and once-daily treatment. Biopharm Drug Dispos 1994;15:45-52.
21. Woehler TR, Eff J, Graney W, Heald D, Ziemniak J, Magner D. Multicenter evaluation of the efficacy and safety of sustained-release diltiazem hydrochloride for the treatment of hypertension. Clin Ther 1992;14:148-57.
22. White WB. Blood pressure load and target organ effects in patients with essential hypertension. J Hypertens 1991;9(suppl 8):s39-41.
23. Omboni S, Parati G, Zanchetti A, Mancia G. Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995;13:1105-12.
24. Zanchetti A. Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. J Hypertens 1994;12(suppl 8):s97-106.
25. Dixon WJ, Brown MB, Engelman L, et al. BMDP statistical software. Berkeley: University of California Press, 1985.
26. Dupont AG, Van der Niepen P, Six RO. Placebo does not lower ambulatory blood pressure. Br J Clin Pharmacol 1987;24:106-9.
27. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995;8:311-5.
28. Staessen JA, Bieniaszewski L, Buntinx F, et al. The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. Hypertension 1995;26(part 1):942-9.
29. Flamenbaum W, Goldstein A, Park G, Willet M, Steward W. Once daily diltiazem: duration, peak (P), and trough (T) blood pressure effects. J Clin Pharmacol 1990;30:856.
30. Massie BM, Der E, Herman TS, Topolski P, Park GD, Steward WH. 24-Hour efficacy of once-daily diltiazem in essential hypertension. Clin Cardiol 1992;15:365-8.
31. Felicetta JV, Serfer HM, Cutler NR, et al. A dose-response trial of once-daily diltiazem. Am Heart J 1992;123:1022-6.
32. Meeves SG, Park GD. The use of confidence intervals to describe the precision of trough/peak ratios for diltiazem CD in the treatment of hypertension. J Clin Pharmacol 1994;34:231-5.
33. Lacourcière Y, Poirier L, Lefebvre J, Burford RG. Clinical efficacy of force titrated doses of diltiazem extended-release: a placebo controlled study. Am J Hypertens 1995;8:282-6.
34. Rose M, McMahon FG. Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990;3:151-5.
35. Coca A. Circadian rhythm and blood pressure control: physiological and pathophysiological factors. J Hypertens 1994;12(suppl 5):s13-21.
36. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987;5:93-8.
37. Kobrin I, Oigman W, Kumar A, et al. Diurnal variation of blood pressure in elderly patients with essential hypertension. J Am Geriatr Soc 1984;32:896-9.
38. Pessina AC, Palatini P, Sperti G, et al. Evaluation of hypertension and related target organ damage by average day-time blood pressure. Clin Exp Hypertens [A] 1985;7:267-71.
39. Glasser SP, Koehn DK. Predictors of left ventricular hypertrophy in patients with essential hypertension. Clin Cardiol 1989;12: 129-32.
40. Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese V. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994;7:23-9.
41. Palatini P, Penzo M, Racioppa A, et al. Clinical relevance of nighttime blood pressure and daytime blood pressure variability. Arch Intern Med 1992;152:1855-60.
42. Shimada K, Kawamoto A, Matsubayashi K, Nishinaga M, Kimura S, Ozawa T. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 1992;10:875-8.
43. Verdecchia P, Schillaci G, Gatteschi C, et al. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation 1993;88:986-92.
44. Perloff D, Sokolow M, Cowan RM. The prognostic value of ambulatory blood pressure. JAMA 1983;249:2792-8.
45. Perloff D, Sokolow M, Cowan RM, Juster RP. Prognostic value of ambulatory blood pressure measurements: further analysis. J Hypertens 1989:7(suppl 3):s3-10.
46. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993;11:1133-7.
47. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994;24:793-801.
48. Kannel WB, Sorlie P, Gordon T. Labile hypertension: a faulty concept? The Framingham study. Circulation 1980;61:1183-7.
49. Pickering TG. Evaluation of antihypertensive treatment by ambulatory monitoring. In: Pickering TG, ed. Ambulatory monitoring and blood pressure variability (part II). London: Science Press, 1990;10.1-10.16.
50. Pickering TG. Diurnal rhythms and other sources of blood pressure variability in normal and hypertensive subjects. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 1990:1397-405.
51. Zanchetti A, Bianchi L, Bozza M, Omboni S, Villani A, Ravogli A, and the Italian Nifedipine GITS Study Group. Antihypertensive effects of nifedipine GITS on clinic and ambulatory blood pressures in essential hypertensives. High Blood Press 1994;3: 1-11.
52. Mancia G, Casadei R, Wutti E, Trazzi S, Parati G. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment. Am J Med 1989;87(suppl 6B):64-9.
53. Clement D, De Buyzere M, Duprez DD. Influence of drugs on blood pressure variability. J Hypertens 1994; 12(suppl 8):s49-53.